^
Association details:
Biomarker:DDR
Cancer:Ovarian Cancer
Drug:elimusertib (BAY 1895344) (ATR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

ELIMUSERTIB, AN ORAL ATAXIA TELANGIECTASIA AND RAD3-RELATED INHIBITOR, IN ADVANCED GYNECOLOGIC CANCERS WITH DNA DAMAGE RESPONSE DEFECTS

Published date:
09/08/2022
Excerpt:
Overall response rate was 2% (1/44 evaluable); 77% of patients had a best response of stable disease. In ovarian cancer patients, the clinical benefit rate at 120 days was 40%, including patients with previous PARPi treatment; 19% of patients had ≥50% reduction in CA-125 levels....Elimusertib demonstrated clinical benefit in heavily pretreated gynecologic cancers with DDR defects.
Trial ID: